2025 / 01 / 23

AJICAP® Second Generation
was awarded in
World ADC conference !


“AJICAP® Second Generation”, a technology to create the next generation ADCs (*1) was awarded in a scientific conference, World ADC held in San Diego (*2), as “Best ADC Preclinical Publication 2023”. Dr. Fujii gave a presentation as a representative of the AJICAP® R&D team in front of an audience of over 1,000 people. “AJICAP® Second Generation” was selected with over 2,500 votes cast and many scientific proposals drafted.

“AJICAP® Second Generation” has the potential to solve clinical issues of previous conventional ADCs with regard to desired biological effects and side effects. This technology has been originally invented in Research Institute for Bioscience Products & Fine Chemicals and developed in collaboration with Ajinomoto Bio-Pharma Services, San Diego for the use by our clients in the pharmaceutical industry.

  1. ADC (Antibody Drug Conjugate): Anti-cancer drugs gathering increasing attention because of the ability to kill cancer cells specifically.
  2. World ADC: The world largest ADC conference

Related information